Skip to main navigation
Sigilon Therapeutics
  • About Us
    • Our Company
      • Leadership
      • Board of Directors
      • Founders
      • Scientific Advisory Board
    • Contact Us
  • Science
    • SLTx PLATFORM
    • Publications
  • Pipeline
  • Patients & Caregivers
    • Overview
    • Meet Our Advocacy Team
    • Rare Blood Disorders
    • Lysosomal Storage Diseases
    • Diabetes
  • Investors/Media
    • Investors/Media Home
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Investor Resources
      • Investor FAQ
      • Email Alerts
  • Inside Sigilon
    • Our Culture
    • Job Opportunities

Press Releases

More news releases are coming soon.

Investors/Media

  • Investors/Media Home
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Analyst Coverage
  • Financials & Filings
    • SEC Filings
    • Quarterly Reports
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Investor Resources
    • Investor FAQ
    • Email Alerts

Investor Contact

Robert Windsor, Jr., J.D.
VP, Head of Investor Relations
Sigilon Therapeutics
Robert.windsor@sigilon.com
617.586.3837
 
 

Media Contact

Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
 
 
©2022 Sigilon Therapeutics, Inc.
sigilon logo
The marks SIGILON THERAPEUTICS, SIGILON, SHIELDED LIVING THERAPEUTICS, SLTX, AFIBROMER, AFIBROTEK, and our logos are trademarks of Sigilon Therapeutics, Inc. in the U.S. and other countries. All other marks are the property of their respective owners.     Privacy Policy